813 Results
Sort By:
Published on June 13, 2017
Quest Diagnostics has agreed to acquire two laboratory businesses in Lewisville, TX, for an undisclosed price, in a deal that will enable the buyer to create a center for cancer precision medicine diagnostic services in the Southwest. Quest plans to acquire MedFusion and Clear Point from co-owners that include Baylor…
Published on June 9, 2017
Foundation Medicine and Caris Life Sciences will alert physicians to patients who are eligible for the National Cancer Institute’s Phase II NCI-MATCH (Molecular Analysis for Therapy Choice) study, through separate collaborations announced this week. The companies said they will inform the physicians, who will work from more than 1,100 clinical…
Published on June 7, 2017
Delivering precision medicine to late-stage cancer patients is the goal of a “turnkey” informatics solution that integrates offerings from both Royal Philips and Navican, a wholly-owned spinout of Intermountain Healthcare. The solution will apply Navican's TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics cloud-based precision medicine platform, which integrates…
Published on June 6, 2017
Genetic data is valuable to physicians, but often difficult to move around because it is so unwieldy. To address that challenge, the Office of the National Coordinator for Health Information Technology (ONC) has launched a 5-pilot project called Sync for Genes. The project will look for ways to use the…
Published on June 5, 2017
A partnership launched by Thermo Fisher Scientific with the Institute of Medical Genetics and Pathology at University Hospital Basel aims to accelerate clinical research into oncology and immuno-oncology by developing and validating next-generation sequencing (NGS)-based cancer diagnostics. The Institute is the first partner in Thermo Fisher Scientific’s Next Generation Sequencing…
Published on June 2, 2017
Aldehydes, a common class of organic compounds, could increase the risk of cancer by obstructing the body’s mechanism for repairing the damage to DNA that arises as human cells divide, according to a study published this week. Aldehydes are produced in small quantities in the body, yet increasingly found everywhere…
Published on May 31, 2017
Oxford Gene Technology (OGT) said today it agreed to be acquired by in vitro diagnostic company Sysmex for an undisclosed price, in a deal that will expand the buyer into the cytogenetics market. By acquiring OGT, Sysmex said, it will enter cytogenetics with both FISH (fluorescence in situ hybridisation) and…
Published on May 12, 2017
Offering Includes Whole Genome Sequencing and Full Body MRI to Give Insight into Cancer, Cardiovascular, Metabolic and Neurological Disease Risk Human Longevity, which focuses on a genomics-based approach to unlocking insights into human health launched Health Nucleus X (HNX) a pilot program designed to provide individuals and their physicians actionable…
Published on April 26, 2017
Molecular diagnostics accounts for only a tenth of the in vitro diagnostics (IVD) market—but most of its hopes for future revenue growth, according to Kalorama Information, which projects the MDx market will balloon to $10 billion by 2021. At 8% growth, molecular diagnostics is expected to double the 4% rate…
Published on April 21, 2017
Paradigm Diagnostics has launched its personalized medicine cancer registry, designed to allow physicians to better collect, share, and visualize oncology data. The Paradigm registry—published in an article entitled “A Prospective Registry Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment of Advanced Solid Tumors”—builds on a study…
Published on April 14, 2017
NantOmics, a molecular diagnostics developer and part of the NantWorks umbrella of nine companies founded by Patrick Soon-Shiong, M.D., has acquired Genos, a Complete Genomics spinout focusing on personal genetic discovery and research, for an undisclosed price. Genos offers whole-exome DNA sequencing through a $499 saliva kit that the company…
Published on April 12, 2017
In today’s drug development landscape, where targeted therapies are increasingly common, partnerships between pharmaceutical and diagnostics companies for the development of a companion diagnostic are on the rise. Clinical OMICs Editor in Chief Chris Anderson recently spoke with David Parker, Ph.D., senior vice president, diagnostics solutions, at Precision for Medicine about…
Published on April 11, 2017
Aprima Medical Software said today it will enable clients to access genomics in everyday patient care and deliver clinically actionable insights by integrating its EHR with the ActX Genomic Decision Support platform, through a partnership whose value was not disclosed. ActX Genomic Decision Support will be available through the Aprima…
Published on April 6, 2017
Molecular diagnostics company Curetis announced it has spun out a new subsidiary, Ares Genetics, which will focus on developing methods to determine the genetic underpinnings of anitbiotic resistance in order to develop testing methods to rapidly detect antibiotic resistance in patients with microbial infections. The new company will build upon…
Published on April 6, 2017
Myriad Genetics said today it will partner with BeiGene to develop companion diagnostics for use with the biopharma’s novel poly ADP-ribose polymerase (PARP) inhibitor BGB-290, through a collaboration whose value was not disclosed. BeiGene has agreed to use Myriad’s myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the…